{"id":"icotinib-hydrochloride-tablets","safety":{"commonSideEffects":[{"rate":"34%","effect":"Diarrhea"},{"rate":"24%","effect":"Nausea"},{"rate":"17%","effect":"Vomiting"},{"rate":"14%","effect":"Fatigue"},{"rate":"12%","effect":"Anorexia"}]},"_chembl":{"chemblId":"CHEMBL4297665","moleculeType":"Small molecule","molecularWeight":"427.89"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Icotinib hydrochloride is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR).","oneSentence":"Tyrosine kinase inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:34:55.652Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT04206072","phase":"PHASE2, PHASE3","title":"D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC","status":"COMPLETED","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2019-12-24","conditions":"Non-Small Cell Lung Cancer, EGFR Gene Mutation","enrollment":362},{"nctId":"NCT02934256","phase":"PHASE2","title":"Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors","status":"COMPLETED","sponsor":"Li Peng","startDate":"2016-07","conditions":"Vestibular Schwannoma, Neurofibromatosis Type 2","enrollment":10},{"nctId":"NCT04575415","phase":"","title":"Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2020-10-07","conditions":"NSCLC","enrollment":272},{"nctId":"NCT04007835","phase":"NA","title":"Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2019-07","conditions":"NSCLC","enrollment":120},{"nctId":"NCT02889692","phase":"PHASE3","title":"Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2013-03","conditions":"Cancer","enrollment":23},{"nctId":"NCT03766490","phase":"NA","title":"Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-03-30","conditions":"Non-Small-Cell Lung","enrollment":66},{"nctId":"NCT02778893","phase":"PHASE4","title":"Conmana Combined With Thalidomide to Treat NSCLC","status":"UNKNOWN","sponsor":"Henan Provincial People's Hospital","startDate":"2016-03","conditions":"NSCLC","enrollment":67},{"nctId":"NCT02375022","phase":"PHASE2","title":"Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2015-03","conditions":"Lung Cancer","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Conmana"],"phase":"phase_2","status":"active","brandName":"Icotinib Hydrochloride Tablets","genericName":"Icotinib Hydrochloride Tablets","companyName":"Betta Pharmaceuticals Co., Ltd.","companyId":"betta-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tyrosine kinase inhibitor Used for Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}